{
    "clinical_study": {
        "@rank": "38669", 
        "arm_group": [
            {
                "arm_group_label": "Sorafenib", 
                "arm_group_type": "Active Comparator", 
                "description": "Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential :  Sorafenib maintenance"
            }, 
            {
                "arm_group_label": "S-1 and Sorafenib", 
                "arm_group_type": "Experimental", 
                "description": "Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to investigate the effect of adjuvant therapy by Sorafenib,\n      Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver\n      transplantation"
        }, 
        "brief_title": "Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  hepatocellular carcinoma after liver transplantation\n\n          -  Major organ (heart, lung and brain) function was normal\n\n        Exclusion Criteria:\n\n          -  Any active infectious process\n\n          -  The presence of clinically confirmed extrahepatic metastasis\n\n          -  Postoperative dysfunction of any organ"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129322", 
            "org_study_id": "ZYYYMedOncoLT01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sorafenib", 
                    "S-1 and Sorafenib"
                ], 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sorafenib", 
                    "S-1 and Sorafenib"
                ], 
                "intervention_name": "S-1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sorafenib", 
                    "S-1 and Sorafenib"
                ], 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Sorafenib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "contact": {
                "last_name": "Weijiafang fang"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China"
                }, 
                "name": "First affiliated hospital, Zhejiang University"
            }, 
            "investigator": {
                "last_name": "Weijia fang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study", 
        "other_outcome": {
            "description": "Circulative tumor cell", 
            "measure": "Circulative tumor cell (CTC) level change", 
            "safety_issue": "No", 
            "time_frame": "within one year after liver transplantation"
        }, 
        "overall_contact": {
            "email": "weijiafang@gmail.com", 
            "last_name": "Weijia fang"
        }, 
        "overall_official": {
            "affiliation": "First affiliated hospital, Zhejiang University", 
            "last_name": "Weijia fang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to Recurrence", 
            "measure": "Time to Recurrence (TTR)", 
            "safety_issue": "No", 
            "time_frame": "within five years after liver transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129322"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Weijia Fang", 
            "investigator_title": "First affiliated hospital, Zhejiang University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Overall survival", 
            "measure": "Overall survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "within the five years after liver transplantation"
        }, 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}